IM19 CAR-T Cells

· Beijing Immunochina Medical Science & Technology Co., Ltd.

Drug timelines are a Plus or Pro feature.

4 regulatory and trial events tracked for IM19 CAR-T Cells, covering 2018-05-01 to 2022-04-04. Get the full timeline:

Most recent: Clinical Trial Update: Clinical Trial to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) B-cell Acute Lymphoblastic Leukemia [Phase 1, Phase 2]

See pricing